YU76404A - Upotreba epotilona u lečenju bolesti mozga povezanih sa proliferativnim procesima - Google Patents

Upotreba epotilona u lečenju bolesti mozga povezanih sa proliferativnim procesima

Info

Publication number
YU76404A
YU76404A YU76404A YUP76404A YU76404A YU 76404 A YU76404 A YU 76404A YU 76404 A YU76404 A YU 76404A YU P76404 A YUP76404 A YU P76404A YU 76404 A YU76404 A YU 76404A
Authority
YU
Yugoslavia
Prior art keywords
treatment
diseases
epothilones
brain
proliferative processes
Prior art date
Application number
YU76404A
Other languages
English (en)
Inventor
Rosemarie Lichtner
Andrea Rotgeri
Ulrich Klar
Jens Hoffmann
Bernd Buchmann
Wolfgang Schwede
Werner Skuballa
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27675676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU76404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of YU76404A publication Critical patent/YU76404A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak obezbeđuje upotrebu Epotilona, koji pokazuje prosečni koeficijent distribucije između plazme i mozga od 0,3 do 1,5 u ogledu intravenoznog ubrizgavanja u bolus miša, za pripremanje medikamenta za lečenje bolesti mozga povezane sa proliferativnim procesima.[This invention provides the use of an Epothilone, which shows an average distribution coefficient between plasma and brain of 0.3 to 1.5 in the mouse intravenous bolus injection assay, for the preparation of a medicament for the treatment of a brain disease associated with proliferative processes.
YU76404A 2002-03-01 2003-02-28 Upotreba epotilona u lečenju bolesti mozga povezanih sa proliferativnim procesima YU76404A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36106202P 2002-03-01 2002-03-01
EP02004745A EP1340498A1 (en) 2002-03-01 2002-03-01 Use of epothilones in the treatment of brain diseases associated with proliferative processes

Publications (1)

Publication Number Publication Date
YU76404A true YU76404A (sh) 2006-08-17

Family

ID=27675676

Family Applications (1)

Application Number Title Priority Date Filing Date
YU76404A YU76404A (sh) 2002-03-01 2003-02-28 Upotreba epotilona u lečenju bolesti mozga povezanih sa proliferativnim procesima

Country Status (23)

Country Link
US (1) US20040019088A1 (sh)
EP (2) EP1340498A1 (sh)
JP (1) JP2005525360A (sh)
KR (1) KR20040095244A (sh)
CN (1) CN100473381C (sh)
AR (1) AR038712A1 (sh)
AU (1) AU2003215618B2 (sh)
BR (1) BR0308154A (sh)
CA (1) CA2477403A1 (sh)
CR (1) CR7444A (sh)
EC (1) ECSP045340A (sh)
HK (1) HK1079998A1 (sh)
HR (1) HRP20040892A2 (sh)
IL (1) IL163752A0 (sh)
MX (1) MXPA04008450A (sh)
NO (1) NO20044175L (sh)
NZ (1) NZ546617A (sh)
PL (1) PL370768A1 (sh)
RU (1) RU2351330C2 (sh)
UA (1) UA83798C2 (sh)
WO (1) WO2003074053A1 (sh)
YU (1) YU76404A (sh)
ZA (1) ZA200407905B (sh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
JP2001512723A (ja) * 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用
AU4101800A (en) * 1999-02-11 2000-08-29 Schering Aktiengesellschaft Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
US7125893B1 (en) * 1999-04-30 2006-10-24 Schering Ag 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE10331004A1 (de) * 2003-07-03 2005-02-24 Schering Ag Verfahren für die Herstellung von C1-C15-Fragmenten von Epothilonen und deren Derivaten
EP1559447A1 (en) * 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US20060069136A1 (en) * 2004-09-24 2006-03-30 Ulrich Klar Use of Epothilones in the treatment of bone metastasis
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP1700596A1 (en) * 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
DE102007016046A1 (de) * 2007-03-30 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung
CN104116736A (zh) * 2008-04-24 2014-10-29 百时美施贵宝公司 埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
WO2013092983A2 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
EP3010548A1 (en) 2013-06-21 2016-04-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT833828E (pt) * 1995-06-09 2003-02-28 Novartis Ag Derivados de rapamicina
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
BR9807418A (pt) * 1997-02-18 2002-01-22 Canji Inc Terapia de gene supressor de tumor combinado e quimioterapia no tratamento de neoplasmas
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001512723A (ja) * 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用
TWI221469B (en) * 1997-12-04 2004-10-01 Bristol Myers Squibb Co A process for the reduction of oxiranyl epothilones to olefinic epothilones
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
WO1999067253A2 (en) * 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
NZ513268A (en) * 1999-02-18 2004-05-28 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
AR023792A1 (es) * 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
EP2266607A3 (en) * 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
GB0013643D0 (en) * 2000-05-31 2000-07-26 Unilever Plc Targeted moieties for use in bleach catalysts
JP2004532888A (ja) * 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体

Also Published As

Publication number Publication date
CR7444A (es) 2005-10-05
AU2003215618A1 (en) 2003-09-16
BR0308154A (pt) 2005-01-04
CN100473381C (zh) 2009-04-01
CN1649587A (zh) 2005-08-03
IL163752A0 (en) 2005-12-18
EP1340498A1 (en) 2003-09-03
CA2477403A1 (en) 2003-09-12
NZ546617A (en) 2007-12-21
HK1079998A1 (zh) 2006-04-21
PL370768A1 (en) 2005-05-30
ECSP045340A (es) 2004-11-26
JP2005525360A (ja) 2005-08-25
US20040019088A1 (en) 2004-01-29
EP1480643A1 (en) 2004-12-01
HRP20040892A2 (en) 2004-12-31
MXPA04008450A (es) 2005-07-13
AR038712A1 (es) 2005-01-26
UA83798C2 (ru) 2008-08-26
RU2004129325A (ru) 2005-07-10
WO2003074053A1 (en) 2003-09-12
ZA200407905B (en) 2006-04-26
RU2351330C2 (ru) 2009-04-10
NO20044175L (no) 2004-12-01
AU2003215618B2 (en) 2009-06-04
KR20040095244A (ko) 2004-11-12

Similar Documents

Publication Publication Date Title
UA83798C2 (ru) Применение эпотилонов в лечении заболеваний мозга, ассоциированных с пролиферативными процессами
NZ595313A (en) The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
LUC00011I1 (sh)
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
TW200801042A (en) Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
WO2005084377A3 (en) Combination therapy with glatiramer acetate and riluzole
WO2004103267A3 (en) Methods to administer epothilone d
NZ542305A (en) Treatment of proliferative diseases with an epothilone derivative and radiation
MXPA05013958A (es) Tratamiento de cancer con epotilona.